Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Sells 881 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Ori Gutwerg sold 881 shares of the business’s stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $60.07, for a total transaction of $52,921.67. Following the completion of the sale, the senior vice president now directly owns 89,897 shares in the company, valued at $5,400,112.79. This represents a 0.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

ANI Pharmaceuticals Stock Up 0.8%

ANI Pharmaceuticals stock opened at $59.99 on Monday. The firm has a market capitalization of $1.31 billion, a PE ratio of -109.07 and a beta of 0.56. The company’s 50-day moving average is $66.91 and its 200-day moving average is $60.79. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $77.00. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.33. The company had revenue of $197.12 million for the quarter, compared to analyst estimates of $179.75 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. ANI Pharmaceuticals’s revenue for the quarter was up 43.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.82 EPS. Sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Hohimer Wealth Management LLC grew its stake in ANI Pharmaceuticals by 5.2% in the 1st quarter. Hohimer Wealth Management LLC now owns 4,989 shares of the specialty pharmaceutical company’s stock valued at $334,000 after buying an additional 247 shares during the last quarter. Exchange Traded Concepts LLC grew its stake in ANI Pharmaceuticals by 2.6% in the 4th quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company’s stock valued at $684,000 after buying an additional 310 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in ANI Pharmaceuticals by 3.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company’s stock valued at $582,000 after buying an additional 364 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in ANI Pharmaceuticals by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company’s stock valued at $246,000 after buying an additional 412 shares during the last quarter. Finally, Natixis Advisors LLC grew its stake in ANI Pharmaceuticals by 2.3% in the 4th quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company’s stock valued at $1,028,000 after buying an additional 417 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on ANIP shares. StockNews.com cut shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, April 24th. JPMorgan Chase & Co. initiated coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 price target on the stock. Guggenheim reiterated a “buy” rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 14th. They issued a “buy” rating and a $80.00 price target on the stock. Finally, Truist Financial lifted their price target on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a “hold” rating in a research note on Monday, April 21st. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $80.13.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.